News from swedish orphan biovitrum ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 02, 2023, 03:20 ET Sobi to present new data at the 2023 EHA congress

Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023,...

May 25, 2023, 07:47 ET Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) today announced that it has commenced a tender offer through its indirect wholly owned...

May 25, 2023, 07:46 ET Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) today announced that it has commenced a tender offer through its indirect wholly owned...

May 19, 2023, 02:12 ET EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog...

May 19, 2023, 01:58 ET EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog...

May 10, 2023, 01:36 ET Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced that it has entered into an agreement and plan of merger with CTI BioPharma...

May 10, 2023, 01:32 ET Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) today announced that it has entered into an agreement and plan of merger with CTI BioPharma...

May 09, 2023, 11:08 ET Bulletin from Swedish Orphan Biovitrum (Sobi)'s Annual General Meeting (AGM)

The Sobi® AGM was convened today on 9 May 2023. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:...

May 09, 2023, 11:05 ET Bulletin from Swedish Orphan Biovitrum (Sobi)'s Annual General Meeting (AGM)

The Sobi® AGM was convened today on 9 May 2023. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:...

Apr 27, 2023, 02:34 ET Sobi publishes Q1 2023 report: Continued solid progress

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2023 First quarter 2023 Total revenue SEK 5,239 M...

Apr 27, 2023, 02:30 ET Sobi publishes Q1 2023 report: Continued solid progress

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2023 First quarter 2023 Total revenue SEK 5,239 M...

Apr 19, 2023, 06:45 ET Invitation: Sobi's Q1 2023 report

Sobi plans to publish its report for the first quarter of 2023 on 27 April 2023 at 08:00 CEST. Investors, analysts and media are invited to...

Apr 09, 2023, 15:47 ET Sobi to streamline nirsevimab contractual arrangements

Sobi® today announced a streamlining and simplification of the contractual economics for nirsevimab. In January 2019, Sobi completed the acquisition...

Apr 09, 2023, 15:44 ET Sobi to streamline nirsevimab contractual arrangements

Sobi® today announced a streamlining and simplification of the contractual economics for nirsevimab. In January 2019, Sobi completed the acquisition...

Apr 03, 2023, 07:10 ET Sobi® publishes Annual and sustainability report for 2022

Under the header of `Inspired by caring, powered by science', Sobi® today published its Annual and sustainability report for 2022 with several...

Apr 03, 2023, 07:04 ET Sobi® publishes Annual and sustainability report for 2022

Under the header of `Inspired by caring, powered by science', Sobi® today published its Annual and sustainability report for 2022 with several...

Mar 30, 2023, 04:01 ET Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the...

Mar 30, 2023, 03:58 ET Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ)

The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the...

Mar 21, 2023, 03:54 ET Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled...

Mar 21, 2023, 03:51 ET Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint: Swedish Orphan Biovitrum AB

Selecta Biosciences, Inc. (NASDAQ: SELB) and Sobi®, today announced positive topline results from the Phase 3 DISSOLVE I & II placebo controlled...

Mar 02, 2023, 02:53 ET Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB

Sobi® and Sanofi today announced that the XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa ...

Mar 02, 2023, 02:51 ET Positive topline results from pivotal XTEND-Kids phase 3 study of efanesoctocog alfa in children under 12 years of age with haemophilia A: Swedish Orphan Biovitrum AB

Sobi® and Sanofi today announced that the XTEND-Kids phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa ...

Feb 24, 2023, 01:30 ET FDA approves once-weekly efanesoctocog alfa, a new class of high-sustained factor VIII therapy for haemophilia A: Swedish Orphan Biovitrum AB

Sobi® today announced that the US Food and Drug Administration (FDA) has approved efanesoctocog alfa [Antihemophilic Factor (Recombinant),...

Feb 08, 2023, 04:23 ET Sobi publishes Q4 and FY 2022 report: a good year and a solid future

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2022 Fourth quarter 2022 Total revenue...

Feb 08, 2023, 04:21 ET Sobi publishes Q4 and FY 2022 report: a good year and a solid future

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2022 Fourth quarter 2022 Total revenue...